The Macula pp 149-170 | Cite as

Interim analysis of the MIRA-1 — multicenter double masked placebo controlled trial of rheopheresis in dry age-related macular degeneration (AMD) with soft drusen

Part of the Framework of Clinical Studies and Investigations to Prove Safety and Efficacy of Rheopheresis as a Novel Treatment Option for AMD
  • Reinhard Klingel


Rheopheresis is a safe and effective modality of therapeutic apheresis to treat microcirculatory disorders. Elimination of a defined spectrum of high molecular weight proteins from human plasma including pathophysiologically relevant risk factors for AMD such as fibrinogen, LDL-cholesterol, α2-macroglobulin, fibronectin, and von-Willebrand factor results in the reduction of blood and plasma viscosity as well as erythrocyte and thrombocyte aggregation. Pulses of lowering blood and plasma viscosity performed as series of Rheopheresis treatments lead to rapid changes of blood flow, with the potential induction of sustained improvement of microcirculation, and recovery of retinal function. Change of the activity of promotors of the natural course of AMD development and progression might represent the mechanism of sustained improvement of microcirculation, i.e. recovery of retinal function. To evaluate safety and efficacy of Rheopheresis for the treatment of dry AMD with soft drusen in the MIRA-1 trial 150 patients are to be randomized in a 2:1 ratio to receive 8 Rheopheresis or 8 sham apheresis treatments over 10 weeks and followed for one year. Investigational sites include 9 study centers and an additional reading center in the US. Qualified patients have dry AMD with multiple large soft drusen, VAC of 0.16–0.625, and for homogeneity of patient groups defined serum levels of selected high-molecular weight plasma proteins. The interim analysis included 43 subjects. In primary eyes the mean ETDRS-line difference at 12 months post baseline between treated and control group was 1.6 lines (p = 0.0011, repeated measures analysis). The difference was significant throughout the first post-treatment year. Subgroup analysis indicated that eyes with baseline VAC worse than 20/40 derived the greatest treatment benefit at one year with mean difference of 3.0 ETDRS-lines compared to placebo (p = 0.001). No severe treatment related adverse events occurred. In conclusion the interim analysis of the MIRA-1 trial demonstrated statistically significant and clinically relevant effects of Rheopheresis on VAC when compared to placebo controls for the 12-month study interval. The framework of completed and still ongoing controlled clinical trials in combination with post certification studies including the RheoNet-registry represents a comprehensive quality management approach for this novel interdisciplinary therapy for AMD. A hypothesis based upon current knowledge of pathogenic mechanisms of the development and progression of AMD can be conclusively linked with the putative mechanism of action of Rheopheresis for AMD. A recommendation for high-risk AMD-patients was defined. Based on the positive results of the MIRA-1 interim analysis 8 Rheopheresis treatments are currently recommended as the initial treatment series.


Retinal Pigment Epithelium Pigment Epithelium Derive Factor Choroidal Blood Flow Pulsatile Ocular Blood Flow Transpupillary Thermotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pfau N, Kupsch S, Kern AO, Beske F (2000) Epidemiology and socioeconomic importance of blindness and severe vision loss in Germany ( Publication in German ). Schriftenreihe des IGSF — Institut für Gesundheits-System-Forschung 84: 1–161Google Scholar
  2. 2.
    Ciulla TA, Harris A, Martin BJ (2001) Ocular perfusion and age-related macular degeneration. Acta Ophthalmol Scand 79: 108–15PubMedCrossRefGoogle Scholar
  3. 3.
    Fine SL, Berger JW, Maguire MG, Ho AC (2000) Age-related macular degeneration. N Engl J Med 342: 483–92PubMedCrossRefGoogle Scholar
  4. 4.
    Sarraf D, Gin T, Yu F, Brannon A, Owens SL, Bird AC (1999) Long-term drusen study. Retina 19: 513–19PubMedCrossRefGoogle Scholar
  5. 5.
    Lanchoney DM, Maguire MG, Fine SL (1998) A model of the incidence and consequences of choroidal neovascularization secondary to age-related macular degeneration. Comparative effects of current treatment and potential prophylaxis on visual outcomes in high-risk patients. Arch Ophthalmol 116: 1045–52PubMedGoogle Scholar
  6. 6.
    Klein R, Klein BEK, Tomany SC, Meuer SM, Huang GH (2002) Ten-year incidence and progression of age-related maculopathy. Ophthalmol 109: 1767–79CrossRefGoogle Scholar
  7. 7.
    Hageman GS, Luthert PJ, Chong NHV, Johnson LV, Anderson DH, Mullins RF (2001) An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degeneration. Prog Ret Eye Res 20: 705–32CrossRefGoogle Scholar
  8. 8.
    Ramirez JM, Ramirez AI, Salazar JJ, de Hoz R, Trivino A (2001) Changes of astrocytes in retinal aging and age-related macular degeneration. Exp Eye Res 73: 601–15PubMedCrossRefGoogle Scholar
  9. 9.
    Eye Disease Case-Control Study Group (1992) Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol 110: 1701–8CrossRefGoogle Scholar
  10. 10.
    Smith W, Mitchell P, Leeder SR, Wang JJ (1998) Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy. Arch Ophthalmol 116: 583–587PubMedGoogle Scholar
  11. 11.
    Vingerling JR, Dielemans I, Bots ML, Homan A, Grobbee DEL, de Jong PTVM (1995) Age-related macular degeneration is associated with atherosclerosis. Am J Epidemiol 142: 404–9PubMedGoogle Scholar
  12. 12.
    Lip PL, Blann AD, Hope-Ross M, Gibson JM, Lip GYH (2001) Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology, and endothelial dysfunction. Ophthalmol 108: 705–10CrossRefGoogle Scholar
  13. 13.
    Baudouin C, Peyman GA, Fredj-Reygrobellet D, Gordon WC, Lapalus P, Gastaud P, Bazan NG (1992) Immunohistochemical study of subretinal membranes in age-related macular degeneration. Jpn J Ophthalmol 36: 443–51PubMedGoogle Scholar
  14. 14.
    Friedman E (1997) A hemodynamic model of the pathogenesis of age-related macular degeneration. Am J Ophthalmol 124: 677–82PubMedGoogle Scholar
  15. 15.
    Grunwald J, Hariprasad S, DuPont J (1998) Effect of aging on foveolar choroidal circulation. Arch Ophthalmol 116: 150–4PubMedGoogle Scholar
  16. 16.
    Grunwald J, Hariprasad S, DuPont J, Maguire M, Fine S, Brucker A, Maguire A, Ho A (1998) Foveolar choroidal blood flow in age-related macular degeneration. Invest Ophthalmol Vis Sci 39: 385–90PubMedGoogle Scholar
  17. 17.
    Chen SJ, Cheng CY, Lee AF, Lee FL, Chou JCK, Hsu WM, Liu JH (2001) Pulsatile ocular blood flow in asymmetric exudative age related macular degeneration. Br J Ophthalmol 85: 141–115CrossRefGoogle Scholar
  18. 18.
    Tamai M, Mizuno K, Chader GJ (1982) In vitro studies on shedding and phagocytosis of rod outer segments in the rat retina: effect of oxygen concentration. Invest Ophthalmol 22: 439–48Google Scholar
  19. 19.
    Sheu SJ, Sakamoto T, Osusky R, Wang HM, Ogden TE, Ryan SJ, Hinton DR, Gopalakrishna R (1994) Transforming growth factor-ß regulates human retinal pigment epithelial cell phagocytosis by influencing a protein kinase C-dependent pathway. Graefe’s Arch Clin Exp Ophthalmol 234: 695–701CrossRefGoogle Scholar
  20. 20.
    Ueba H, Kawakami M, YaginumaT (1997) Shear stress as an inhibitor of vascular smooth muscle cell proliferation. Role of transforming growth factor beta 1 and tissue-type plasminogen activator. Arterioscler Thromb Vasc Biol 17: 1512–16PubMedCrossRefGoogle Scholar
  21. 21.
    Moore DJ, Clover GM (2001) The effect of age on the macromolecular permeability of human Bruch’s membrane. Invest Ophthalmol Vis Sci 42: 2970–5PubMedGoogle Scholar
  22. 22.
    King GL, Suzuma K (2000) Pigment-epithelium-derived factor — a key coordinator of retinal neuronal and vascular functions. N Engl J Med 342: 349–51PubMedCrossRefGoogle Scholar
  23. 23.
    Hussain AA, Rowe L, Marshall J (2002) Age-related alterations in the diffusional transport of amino acids across the human Bruch’s-choroid complex. J Opt Soc Am A Opt Image Sci Vis 19: 166–72PubMedCrossRefGoogle Scholar
  24. 24.
    Preissner KT, Pötsch B (1995) Vessel wall-dependent metabolic pathways of the adhesive proteins von-Willebrand factor and vitronectin. Histol Histopathol 10: 239–51PubMedGoogle Scholar
  25. 25.
    Stockmann A, Hess S, Declerck P, Timpl R, Preissner KT (1993) Multimeric vitronectin. J Biol Chem 268: 22874–82PubMedGoogle Scholar
  26. 26.
    Kost C, Benner K, Stockmann A, Linder D, Preissner KT (1996) Limited plasmin proteolysis of vitronectin — characterization of the adhesion protein as morpho-regulatory and angiostatinbinding factor. Eur J Biochem 236: 682–8PubMedCrossRefGoogle Scholar
  27. 27.
    Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT (1996) Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nature Medicine 2: 529–33PubMedCrossRefGoogle Scholar
  28. 28.
    Johnson LV, Leitner WP, Staples MK, Anderson DH (2001) Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Exp Eye Res 73: 887–96PubMedCrossRefGoogle Scholar
  29. 29.
    Age-Related Eye Disease Study Research Group (2001) A randomized, placebo-controled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol 119: 1417–36Google Scholar
  30. 30.
    Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2002) Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Three-year results of an open-label extension of 2 randomized clinical trials — TAP report no.5. Arch Ophthalmol 120: 1307–14Google Scholar
  31. 31.
    Currie ZI, Rennie IG, Talbot JF (2000) Retinal vascular changes associated with transpupillary thermotherapy for choroidal melanomas. Retina 20: 620–6PubMedGoogle Scholar
  32. 32.
    Guymer RH, Hageman GS, Bird AC (2001) Influence of laser photocoagulation on choroidal capillary cytoarchitecture. Br J Ophthalmol 85: 40–6PubMedCrossRefGoogle Scholar
  33. 33.
    Kaga T, Fonseca RA, Dantas MA, Spaide RF (2001) Transient appearance of classic choroidal neovascularization after transpupillary thermotherapy for occult choroidal neovascularization. Retina 21: 172–3PubMedCrossRefGoogle Scholar
  34. 34.
    Kaiser RS, Berger JW, Maguire MG, Ho AC, Javornik NB (2001) Laser burn intensity and the risk for choroidal neovascularization in the CNVPT fellow eye study. Arch Ophthalmol 119: 826–32PubMedGoogle Scholar
  35. 35.
    Klingel R, Fassbender C, Faßbender T, Erdtracht B (2000) Rheopheresis — rheologic, functional and structural aspects. Therapeutic Apheresis 4: 348–57PubMedCrossRefGoogle Scholar
  36. 36.
    Klingel R, Mumme C, Faßbender T, Himmelsbach F, Altes U, Lotz J, Pohlmann T, Beyer J, Kästner E (2003) Rheopheresis in patients with ischemic diabetic foot syndrome — results of an open label prospective pilot trial. Therapeutic Apheresis and Dialysis 7: 444–55PubMedCrossRefGoogle Scholar
  37. 37.
    Lüke C, Widder RA, Soudavar F, Walter P, Brunner R, Borberg H (2001) Improvement of macular function by membrane differential filtration in diabetic retinopathy. J Clin Apheresis 16: 23–8PubMedCrossRefGoogle Scholar
  38. 38.
    Brunner R, Widder RA, Walter P, Lüke C, Godehardt E, Bartz-Schmidt K-U, Heimann K, Borberg H (2000) Influence of membrane differential filtration on the natural course of age-related macular degeneration — a randomized trial. Retina 20: 483–91PubMedGoogle Scholar
  39. 39.
    Swartz M, Rabetoy G (1999) Treatment of non-exudative age-related macular degeneration using membrane differential filtration apheresis. Invest Ophthalmol Vis Sci 40: 319 (abstract)Google Scholar
  40. 40.
    Brunner R, Widder RA, Fischer RA, Walter P, Bartz-Schmidt K-U, Heimann K (1996) Clinical efficacy of haemorheological treatment using plasma exchange, selective adsorption and membrane differential filtration in maculopathy, retinal vein occlusion and uveal effusion syndrome. Transfus Sci 17: 493–8PubMedGoogle Scholar
  41. 41.
    Soudavar F, Widder RA, Brunner R, Walter P, Bartz-Schmitz KU, Borberg H, Heimann K (1998) Changes of retinal haemodynamics after elimination of high molecular weight proteins and lipids in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 39: 386 (abstract)Google Scholar
  42. 42.
    Fell A, Engelmann K, Richard G, Fassbender C, Wahls W, Klingel R (2002) Rheopheresis — a sytemic approach to therapy of age-related macular degeneration. Ophthalmologe 99: 780–4PubMedCrossRefGoogle Scholar
  43. 43.
    Abdelsalam A, Del Priore L, Zarbin MA (1998) Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Sury Ophthalmol 44: 1–29CrossRefGoogle Scholar
  44. 44.
    Widder RA, Farvili E, Reis RGJ, Like C, Walter P, Kirchhof B, Borberg H, Brunner R (2002) The treatment of age-related macular degeneration (ARMD) with extracorporeal treatment procedures. A follow-up of four years. Invest Ophthalmol Vis Sci 43: 2906 (abstract)Google Scholar
  45. 45.
    Godehardt E, Messner H, Wallstab UH (1993) Extracorporeal LDL cholesterol elimination by membrane differential filtration. In: Gotto AM, Mancini M, Richter WO, Schwandt P (eds) Treatment of severe dyslipoproteinemia in the prevention Of coronary heart disease. 4: 208–12Google Scholar
  46. 46.
    Berrouschot J, Barthel H, Scheel C, Köster J, Schneider D (1998) Extracorporeal membrane differential filtration — a new and safe method to optimize hemorheology in acute ischemic stroke. Acta Neurol Scand 97: 126–30PubMedCrossRefGoogle Scholar
  47. 47.
    Suckfüll M for the Hearing Loss Study Group (2002) Fibrinogen and LDL-apheresis in treatment of sudden hearing loss: a randomized multicentre trial. Lancet 360: 1811–17CrossRefGoogle Scholar
  48. 48.
    Ohno-Matsui K, Morita I, Tombran-Tink J, Mrazek D, Onodera M, Uetama T, Hayano M, Murota SI, Mochizuki M (2001) Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 189: 323–33PubMedCrossRefGoogle Scholar
  49. 49.
    Mann H, Bosch Th, Braun N, Fassbinder W, Klingel R, Klinkmann J, Lonnemann G, Querfeld U, Ramlow W, Schettler V (2002) Apheresis-standard of the German society for clinical nephrology. Mitteilungen der Deutschen Arbeitsgemeinschaft für Klinische Nephrologie XXXI/2002: 103–38 (Article in German)Google Scholar

Copyright information

© Springer-Verlag/Wien 2004

Authors and Affiliations

  1. 1.Apheresis Research InstituteCologneGermany

Personalised recommendations